Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Heart Ventricle Remodeling
100%
Dapagliflozin
64%
Placebo
57%
Diabetes Mellitus
50%
Cotransporter
50%
Non Insulin Dependent Diabetes Mellitus
25%
Antidiabetic Agent
14%
Ketone Body
8%
Left Ventricular Systolic Dysfunction
8%
Loop Diuretic Agent
8%
Phase IV
7%
Controlled Clinical Trial
7%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
7%
Clinical Trial
7%
Cardiovascular Disease
7%
Medicine and Dentistry
Heart Ventricle Remodeling
50%
Congestive Heart Failure
50%
Diabetes Mellitus
50%
Cotransporter
50%
Antidiabetic Agent
14%
Cardiovascular System
14%
Dapagliflozin
14%
Cardiovascular Disease
7%
Osmotic Diuresis
7%
Blood Pressure Reduction
7%
Heart Left Ventricle Ejection Fraction
7%
Placebo
7%
Clinical Trial
7%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
7%
Cardiac Magnetic Resonance Imaging
7%
Controlled Clinical Trial
7%
Heart Preload
7%
Diabetes
7%
Quality of Life Measure
7%
Arterial Stiffness
7%
Exercise Tolerance
7%
Exercise Test
7%
Cardiovascular Effect
7%
End-Diastolic Volume
7%